Nestlé Buyback Nestlé will run a $20 billion share buyback from 2020-22 following the sale of its skin health division. The world's biggest food firm, which CEO Mark Schneider has been turning around for the last few years, also confirmed its annual targets. Financial Times
Nestlé CEO Mark Schneider, Nestlé's CEO, sets out his views on the pandemic and effects, along with many other issues, in this fascinating interview with Fortune 's Beth Kowitt. Schneider on Nestlé maintaining its guidance for the year, while many other firms did not: "It was important to me that one of the ways as a company we can contribute to stability is by fully meeting our commitments. In Europe there was a debate that some companies should delay or reduce the dividends. We didn’t do that, because it’s someone else’s income." Fortune
Nestlé buy Nestlé Health Science is to buy out the Californian biopharmaceutical company Aimmune at a valuation of $2.6 billion. Nestlé had already invested $473 million in the company, which makes a treatment called Palforzia, for peanut allergies in children and teens. Aimmune got FDA approval for Palforzia in January. CNBC
$4.3B for bottled water:That’s the price tag Nestle put on its American water brands, which it agreed to sell to a group of private equity firms in an effort to focus on its -- get this --premium water lineup.